Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions

Coronary Artery Disease Clinical Trial

— DCB-BIF  

Official title:

Comparison of Noncompliant Balloon With Drug-coating Balloon Angioplasties for Side Branch After Provisional Stenting for Patients With True Coronary Bifurcation Lesions

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04242134
• Other study ID #: NFH20191128
• Status: Recruiting
• Phase: N/A
• Start date: September 8, 2020
• Est. completion date: June 30, 2026

Study information

• Verified date: May 2023
• Source: Nanjing First Hospital, Nanjing Medical University
• Contact: Shao-Liang Chen, MD, PhD
• Phone: +86-25-52208048
• Email: chmengx[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is designed to investigate whether drug-coated balloon (DCB) compared to conventional balloon angioplasty for side branch after provisional stenting will lead to lower rates of the composite endpoint of major adverse cardiac event (MACE) at 12 months. The individual components of MACE include cardiac death, myocardial infarction (MI), or target lesion revascularization (TLR). True bifurcation lesions were defined according to Medina classification.

Description:

This is a prospective, multi-center, randomized-controlled, single blind, superiority trial that will include 25 international sites. The investigators aim to enroll 784 subjects with true coronary bifurcation lesions in native coronary arterial segments. All patients with true coronary bifurcation lesions suitable for angioplasty will undergo 1:1 randomization either to PS (provisional stenting)-DCB or PS-NCB (noncompliant balloon) group using a randomization schedule blocked by site. All subjects will be screened according to the predefined inclusion and exclusion criteria per protocol and will further undergo angiography after successful stenting of the main vessel with ostium side branch visually estimated stenosis ≥70%. Data and images will be collected during the index procedure, during re-intervention in the case of clinically driven revascularization, and at the predefined 12-month clinical follow-up visit. All subjects will also undergo angiographic follow-up at 13 months.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 784
• Est. completion date: June 30, 2026
• Est. primary completion date: June 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subject must be age =18 years.

2. Subject has silent ischemia, or stable/unstable angina, or acute MI older than 1-week from the onset of chest pain to admission.

3. Subject (or legal guardian) understands the trial design and treatment procedures and provides written informal consent before any trial-specific tests or procedures are performed.

4. Subject is willing to comply with all protocol-required follow-up evaluations.

5. Target lesion must be a true bifurcation lesion on coronary angiography (defined as Medina 0,1,1, Medina 1,0,1, or Medina 1,1,1 coronary bifurcation lesions) and is eligible for percutaneous coronary intervention (PCI).

6. Target lesion reference vessel diameter (both main vessel and side branch) = 2.5 mm by visual estimation.

7. Target lesion must have visually estimated stenosis =50%.

8. Target lesion length of side branch must be <10 mm by visual estimation.

9. Ostium side branch must have visually estimated stenosis =70% after stenting of the main vessel.

Exclusion Criteria:

1. Patient with STEMI (within 1-week from the onset of chest pain to admission).

2. Patient has known allergy to the study balloon/stent system or protocol-required concomitant medications.

3. Patient is intolerable to dual anti-platelet therapy.

4. Patient has any other serious medical illness that may reduce life expectancy to less than 12 months.

5. Patient is pregnant or nursing.

6. Patient is participating in another clinical trial that has not reached its primary endpoint within 24 months after the index procedure.

7. Patient has a planned procedure that may cause non-compliance with the protocol or confound data interpretation.

8. Restenotic lesion.

9. Chronic total occlusion (CTO) lesion in either main vessel or side branch is not successfully recanalized.

10. Severe calcification needing rotational atherectomy.

Related Conditions & MeSH terms

• Coronary Artery Disease

Intervention

Device:
• Drug-coating balloon
Provisional stenting technique with DCB

Locations

Country	Name	City	State
China	Nanjing First Hospital	Nanjing	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
Nanjing First Hospital, Nanjing Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Rate of Angiographic success	PCI is considered successful for lesions treated with stent implantation if the residual diameter stenosis based on visual estimation is less than or equal to 10% and the final TIMI flow grade is 3. PCI is considered successful for lesions treated without stent implantation if the residual diameter stenosis based on visual estimation is less than or equal to 20% and the final TIMI flow grade is 3.	1 day
Other	Rate of clinical procedural success	Successful PCI without MACE during hospital stay.	7 day
Other	Crossover rate	From single stent technique to two-stent technique	1 day
Primary	Rate of major adverse cardiac event	MACE defined as the composite of cardiac death, myocardial infarction (MI), and clinically driven TLR.	12 months after angioplasty
Secondary	Rate of all-cause death or cardiac death	In general, all deaths are considered cardiac unless an alternate cause is unequivocally established, even among subjects with serious noncardiac comorbidities.	12 months after angioplasty
Secondary	Rate of periprocedural MI, Spontaneous MI, or target vessel MI	According to the DCB-BIF trial definition.	12 months after angioplasty
Secondary	Rate of clinically-driven TLR or TVR	Clinically driven revascularization includes repeat PCI or coronary artery bypass graft (CABG) for recurrent or persistent symptomatic ischemia and can be defined according to the relationship to the index PCI (target lesion).	12 months after angioplasty
Secondary	Rate of thrombosis	The safety endpoint was stent thrombosis (ST), according to the definition by Academic Research Consortium.	12 months after angioplasty